多形体筛查

开发一种药物并将其推入市场并不是一件容易的事情，尤其是我们当前所处的环境是在西方的生产标准之下。法律环境和公众意念都对制造业有了很强烈的要求。很少有其它的行业，在被要求快速无误工作的同时，还要面对如此详细的审查和规章制度。那些因操作程序或设计不精确导致后期药物研发终止或临床试验冗余的公司，面临着艰巨的增加上市产品、树立和维持投资者信心的挑战。

Screening for polymorphs

Developing a drug and bringing it to market is not an easy task, especially given the current environment in which we are operating in the west. The regulatory environment and public sentiment are placing intense demands on the industry. Few other industries face such scrutiny and regulation while also being asked to conduct work at breakneck speeds with no errors. Companies who undergo late-stage drug terminations or clinical trial redundanciesduetoprocedural or design inaccuracies face a tough uphill battle in commercialising products and building or maintaining investor confidence.